How Quickly Will I Lose Weight on Wegovy?

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight loss on semaglutide (the active ingredient in Wegovy) begins within the first few weeks, though the pace varies by person. Clinical trials show that patients using GLP-1 receptor agonists lose an average of 15–22% of their starting body weight over 68 weeks—significantly more than diet and exercise alone.

When Do Wegovy Results Appear?

Most people experience their first noticeable weight loss between weeks 2 and 4 of semaglutide therapy. During this window, appetite suppression begins as the medication activates GLP-1 receptors in the brain's satiety centers, reducing hunger cues and food cravings. You may find yourself naturally eating smaller portions or feeling full earlier in meals.

By the end of the first month, typical weight loss ranges from 5 to 10 pounds, though this varies based on starting weight, metabolism, and adherence to healthy eating habits. The medication works alongside behavior change—it doesn't work alone without dietary modifications and physical activity. Starting at PlexusDx's entry dose for compounded semaglutide injection ($189/month) means you begin at a lower strength, allowing your body to adjust before gradual increases.

Expected Weight Loss by Month on Semaglutide

Month 1: Most patients lose 5–10 pounds as appetite suppression kicks in. Month 2–3: Weight loss accelerates to 10–15 total pounds as your body becomes accustomed to smaller food intake and reduced cravings. Months 4–6: Many people reach 20–30 total pounds lost as the metabolic effects of GLP-1 activation compound over time.

By month 3, clinical trial participants using semaglutide showed an average weight loss of 5–7% of body weight. Sustained use through 6 months typically yields 10–15% body weight reduction. Results continue improving through month 12, when average losses reach 15–22% of starting weight in clinical settings. Your individual timeline depends on baseline metabolism, genetic predisposition to GLP-1 pathway sensitivity, and consistency with the medication regimen.

Factors That Speed Up or Slow Down Weight Loss

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Consistent physical activity, adequate sleep, and protein intake optimize results beyond the medication alone. Stress levels, existing metabolic conditions, and medication adherence directly impact the rate of weight loss. Some patients experience a plateau around month 4–6, which typically resolves as doses increase or as your body adapts to lower calorie intake. PlexusDx customers can discuss personalized optimization strategies based on their genetic profile and response trajectory.

Is Faster Weight Loss Always Better?

Gradual, steady weight loss of 1–2 pounds per week is considered safer and more sustainable than rapid drops. Semaglutide's mechanism—reducing appetite rather than forcing weight loss—naturally produces this moderate pace, which preserves lean muscle mass better than crash dieting. Rapid weight loss increases risk of nutritional deficiencies, gallstones, and loose skin.

The goal with GLP-1 therapy is not speed but lasting metabolic reset and behavior change. Many patients continue losing weight 12–18 months into treatment as their relationship with food normalizes. PlexusDx's tiered pricing ($189/month for compounded semaglutide injection) means your dose can increase as needed without increasing your monthly cost, supporting long-term, sustainable results rather than short-term extremes.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I expect to lose in the first month on Wegovy?

Most patients lose 5–10 pounds in month 1 as appetite suppression activates. Results vary based on starting weight and how strictly you follow a reduced-calorie diet alongside the medication. PlexusDx's compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), allowing you to begin at lower doses that gradually increase without price changes.

When will I see visible changes in how my clothes fit?

Visible fit changes typically appear by week 4–6 as you lose 8–15 pounds. Changes become noticeable to others around week 8–12 when cumulative loss reaches 15–25 pounds. Factors like starting weight, muscle gain from exercise, and how fat distributes on your body affect the timeline for visible results.

Is there a weight loss plateau on semaglutide, and when does it happen?

Plateaus are common around months 4–6 as your body adapts to lower calorie intake. They typically resolve within 2–4 weeks with increased physical activity, diet adjustments, or dose escalation. This is a normal part of the process and does not indicate treatment failure.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test ($298) analyzes 14 metabolic pathways including GIPR, FTO, and MC4R variants that influence semaglutide response speed. Knowing your genetic profile helps personalize expectations and optimize your treatment strategy.

What if I'm not losing weight after two months on semaglutide?

No weight change after 8 weeks warrants a dose review or exploration of dietary barriers. Some patients need higher doses to achieve appetite suppression; others benefit from switching to tirzepatide (which targets dual pathways) or oral formulations. PlexusDx serves all 50 states without insurance and can adjust your treatment plan based on your individual response.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.